Humanigen Inc. (HGEN) Highlights Prelim. Results from Ifabotuzumab Phase I Study at AACR Meetings
Tweet Send to a Friend
Humanigen, Inc., (HGEN) announced today that preliminary results from an ongoing phase I bioimaging study of the company’s proprietary anti-EphA3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
